Laminate Medical Technologies was founded to develop solutions for the most significant challenges preventing fistula use in dialysis patients. Laminate’s flagship product, VasQ External Support, was designed to address the high rate of primary fistula failure and repeat procedures experienced by hemodialysis patients. Primary fistula failure rates have been estimated as high as 60% with most patients requiring frequent additional procedures to make the fistula functional. However, clinical results have demonstrated fistulas treated with VasQ have a significantly greater probability for success in becoming functional without the need for additional procedures. VasQ was granted FDA De Novo approval and is available for sale in the United States, Singapore, Europe, Africa and the UK.